Basilea announces submission of Investigational New Drug application for novel oncology drug candidate BAL0891

by NASDAQ Market News November 16, 2021

NASDAQ Market News
Click here to email author

OSE Immunotherapeutics Presented New Translational Data on Tedopi® and Preclinical Data on PD-1/IL-7 Bifunctional Program BiCKI®-IL-7

Press release Biocartis Group NV: New Study Demonstrates Idylla™ EGFR Mutation Test (CE-IVD) Shortens Time to Patient Management Decisions for Patients with Non-Small Cell Lung Cancer

Ads